

Roberto Pistolesi

Partner and CEO
Head of Patent Department



Qualification

Degree in bio-organic chemistry
(Università degli Studi of Milan)

European Patent and Trademark Attorney
Community Design Attorney
Italian Patent and Trademark Agent
Admitted before UIBM, EPO, EUIPO, WIPO
and USBM

Secretary general of FICPI since 2015
Adjunct professor at Università degli
Studi of Milan (2011–2015)
Technical expert of the Court of Milan
and Venice
European Patent Litigator CEIPI diploma

He has published several articles on “Il
Sole–24 Ore”, “Pharmachem” and “Il
Diritto Industriale”.

Associations

- **Ordine dei Consulenti in Proprietà Industriale** (Italian Industrial Property Consultants Institute)
- **Collegio Italiano dei Consulenti in Proprietà Industriale** (Italian association representing FICPI at national level)
- **AIPPI** (International Association for the Protection of Intellectual Property)
- **FICPI** (International Federation of Intellectual Property Attorneys) – **President**
- **FICPI** (International Federation of Intellectual Property Attorneys) – **Secretary General** (2015–2022)
- **Board of Chemists** (1996–2017)

Contacts



pistolesi@dragotti.com



+ 39 02 29014418

Focus On

Chemical
Pharmaceutical
Biotech

Headquarters

Milan

Foreign Languages

Italian
English
French

1994 – 1995

He worked for Fedegari Autoclavi Spa and Nalco

1995

He joined **Dragotti & Associati**

2011 – 2015

He was adjunct Professor at the “Università degli Studi” of Milan, where taught a course on chemical patent practice to the students of Chemical Science, Biotechnology and Industrial Chemistry

2012 – 2015

He was the chairman of FICPI’s study and work commission dealing with inventions in the pharmaceutical and biotechnology area. He frequently lectures on intellectual property both in Italy and abroad

2015

He was elected Secretary General of FICPI

2022

He was elected President of FICPI

Expertise

Extensive experience both in prosecution and opposition procedures before the EPO as well as in patent litigations; in particular, he has been involved in patent litigations concerning the following active principles: alendronic acid (Fosamax), alirocumab (Pralent), atorvastatine (Torvast), cefaclor, citalopram (Celexa), docetaxel (Taxotere), enoxaparine (Lovenox), esomeprazole (Nexium), everolimus (Linevero), phosphatidylserine, gabapentin (Neurontin), irbesartan+HCTZ (Co-Aprovel), latanoprost (Xalatan), olanzapine (Zyprexa), omega-3, omeprazole (Omeprazen), montelukast (Singulair), natalizumab (Tysabri), quetiapine (Seroquel), ramipril, repaglinide (Novonorm), rupatadine, salmeterol + fluticasone, sildenafil (Viagra), tadalafil (Cialis) and terbinafine (Lamisil). Specialized in patent strategies, infringement and validity opinions. Extensive experience in the field of Supplementary Protection Certificates